NewTimeSpace News: CITIC SEC announced the completion of the issue of 803,725,383 new H shares to CITIC Financial Holdings on 6 August 2026 at an issue price of HKD 23.13 per share, with total proceeds of RMB 16 billion and net proceeds of approximately HKD 18.413 billion; following completion, CITIC Financial Holdings holds approximately 23.96% of the Company, with the new H shares subject to a 48-month lock-up; all net proceeds will be retained overseas for international business development, including capital injection of up to RMB 16 billion into CITIC Securities International.
NewTimeSpace News: HANSOH PHARMA announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, has received the Drug Clinical Trial Approval Notice from the NMPA, intended for clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults, marking new progress in its R&D.
NewTimeSpace News: HAOHAI BIOTEC announced that its controlling subsidiary Saimaishi has obtained an NMPA medical device registration certificate for its trifocal toric IOL (valid until 3 August 2031), which passed the special review procedure for innovative medical devices and is the first domestically approved trifocal toric IOL in China; the Company has formed a high-end refractive IOL product matrix covering monofocal through multifocal toric correction; as the product has not yet generated sales, it will not materially affect near-term results.
NewTimeSpace News: TRIUMPH NEW EN announced that it has received a regulatory warning letter from the CSRC Henan Bureau for untimely disclosure, as cumulative litigation and arbitration over 12 months reached RMB 333 million (10.73% of the absolute value of the latest audited net assets); Chairman Mr. Xie Jun, General Manager Mr. Chen Peng and Board Secretary Mr. Chen Hongzhao were held primarily responsible for failing to perform duties diligently; the Company must submit a written rectification report within 15 working days.
NewTimeSpace News: C FIN SERVICES announced that its wholly-owned subsidiary Shenzhen Lingda Small Loans granted a loan of RMB 8.3 million with a six-month term to Customer GL at an annual interest rate of 12%, secured by a residential property mortgage in Nanshan, Shenzhen (valued at approximately RMB 10.461 million); as the applicable percentage ratio exceeds 5% but is below 25%, the loan constitutes a discloseable transaction.
NewTimeSpace News: MEDIA CHINESE(00685.HK) announced the completion of the proposed disposal of a property in Canada on 6 August 2026; upon completion, the vendor is no longer the owner of the property; the disposal constitutes a discloseable transaction.
NewTimeSpace News: Linmon Media Limited announced on 6 August that it expects net profit, net profit attributable to owners and adjusted net profit for the six months ended 30 June 2026 to range from approximately RMB20 million to RMB40 million.
NewTimeSpace News: S HARBOURHOLD(01663.HK) announced that chairman and major shareholder Mr. Wang Linbing purchased 9,446,000 ordinary shares of the Company in the open market on 6 August 2026, at an average price of approximately HKD 0.052 per share and a highest price of HKD 0.055 per share; Mr. Wang is the husband of major shareholder Ms. Chen Xiangling and the father of executive director Mr. Wang Lei.
NewTimeSpace News: Nuobikan Artificial Intelligence Technology announced on 6 August that the Company has entered into a software sales agreement with a domestic AI chip enterprise. The total contract value amounts to RMB50.8 million (tax inclusive), covering the supply of self-developed AI industrial software and supporting technical services.
NewTimeSpace News: Creality 3D Technology announced on 6 August that it expects to record a loss attributable to owners of the Company of approximately RMB53 million to RMB63 million for the six months ended 30 June 2026.
NewTimeSpace News: C C Land Holdings announced on 6 August that it expects to record a net profit attributable to shareholders of approximately HK$30 million for the six months ended 30 June 2026, compared with a net loss of around HK$37 million in the same period last year, marking a swing from loss to profit.
NewTimeSpace News: Sino Biopharmaceutical announced on 6 August that the second-generation flurbiprofen patch (brand name: Zeptis®) developed by its subsidiary Beijing Tide Pharmaceutical has obtained marketing approval from the National Medical Products Administration (NMPA), together with a 4-year data protection period.
NewTimeSpace News: WK GROUP announced the appointment of Shousheng Capital Group Limited as the independent financial adviser to advise the independent board committee on whether the Offer is fair and reasonable and whether to accept the Offer; Shousheng Capital is a licensed corporation permitted to carry out Type 1 and Type 6 regulated activities; its opinion letter will be included in the composite document.
NewTimeSpace News: Liaoning Port (02880.HK) announced that as at the date of the announcement, the market value of H‑shares held by the public and listed on HKEX amounted to approximately HK$755 million, representing about 3.67% of the total issued H‑shares of the class, still below the minimum public float requirement under the Listing Rules. The Company is actively pursuing feasible remedies including major shareholders’ H‑share disposals, H‑share seasoned offering and A‑share repurchase and cancellation. HKEX has agreed to grant a temporary transitional arrangement.
NewTimeSpace News: SICHUAN EXPRESS announced the resignation of non-executive director Mr. Li Chengyong due to work reassignment, effective 6 August 2026; Mr. Li confirmed no disagreement with the Board and no other matters requiring attention; the Board expressed sincere gratitude for his contributions during his tenure.
NewTimeSpace News: SSY GROUP announced that four products received NMPA drug manufacturing registration approvals, all deemed to have passed the consistency evaluation; the Potassium Chloride Injection (II) represents the second domestic enterprise approval, further strengthening the therapeutic infusion layout in the ICU field; both Sodium Hyaluronate Eye Drops feature single-dose preservative-free packaging, forming a stratified dry eye treatment portfolio together with previously approved products; the approval of Metoclopramide Tablets marks the realization of API-to-formulation vertical integration.
